A Child with Papillary Thyroid Carcinoma: Role of Radioactive Iodine Therapy in Pediatric Patients

2018 ◽  
pp. 415-418
Author(s):  
Çiğdem Soydal ◽  
Elgin Özkan
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Pediatric Patients ◽  
Radioactive Iodine ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid

Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma

2016 ◽  
Vol 82 (9) ◽  
pp. 807-814 ◽  
Author(s):  
Paritosh Suman ◽  
Chi-Hsiung Wang ◽  
Tricia A. Moo-Young ◽  
Richard A. Prinz ◽  
David J. Winchester
Keyword(s):  
Overall Survival ◽  
Survival Analysis ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Low Risk ◽  
Intermediate Risk ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid ◽  
Risk Patients

There is no consensus regarding the timing of adjuvant radioactive iodine therapy (RAI) therapy in low- and intermediate-risk papillary thyroid carcinoma (PTC). We analyzed the impact of adjuvant RAI on overall survival (OS) in low- and intermediate-risk PTC. The National Cancer Data Base was queried from 2004 to 2011 for pN0M0 PTC patients having near/subtotal or total thyroidectomy and adjuvant RAI. Tumors ≤1 cm with negative margins were low risk while 1.1- to 4-cm tumors with negative margins or ≤1 cm with microscopic margins were termed intermediate risk. RAI in ≤3 months and between 3 and 12 months was termed as early and delayed, respectively. Survival analysis was performed after adjusting for patient and tumor-related variables. There were 7,306 low-risk and 16,609 intermediate-risk patients. Seventeen per cent low-risk and 15 per cent intermediate-risk patients had delayed RAI. Kaplan-Meier analysis did not show a difference in OS for early versus delayed RAI administration in low- (10-year OS 94.5% vs 94%, P = 0.627) or intermediate-risk (10-year OS 95.3% vs 95.9%, P = 0.944) patients. In adjusted survival analysis, RAI timing did not affect OS in all patients (hazard ratios = 0.98, 95% confidence interval = 0.71–1.34, P = 0.887). In conclusion, the timing of postthyroidectomy adjuvant RAI therapy does not affect OS in low- or intermediate-risk PTC.

scholarly journals Management of Papillary Carcinoma of Thyroid with Pulmonary Metastases in Institute of Nuclear Medicine and Allied Sciences, Rajshahi – Two Case Reports

2018 ◽  
Vol 18 (2) ◽  
pp. 179-182
Author(s):  
Md Kabiruzzaman Shah ◽  
Nasrin Begum ◽  
Mosharof Hossain ◽  
Parvez Ahmed ◽  
Sariful Islam Chawdhuary ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Carcinoma ◽  
Radioactive Iodine ◽  
Pulmonary Metastases ◽  
Case Reports ◽  
Young Patients ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid

Papillary thyroid carcinoma with pulmonary metastasis is relatively uncommon which can be treated with radioactive iodine therapy. Here, our experiences with two cases of papillary thyroid carcinoma with pulmonary metastases in young patients are discussed.Bangladesh J. Nuclear Med. 18(2): 179-182, July 2015

scholarly journals Intraparotid Recurrence of Papillary Thyroid Carcinoma After Thyroidectomy Coincident With Declining Thyroglobulin Levels: A Case Report and Review of the Literature

2021 ◽  
pp. 014556132110331
Author(s):  
Azmi Marouf ◽  
John C. Heaphy ◽  
Abdullah Mohammed Sindi ◽  
Ahlam Hadi Alamri ◽  
Firas R. Abi Sheffah ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Completion Thyroidectomy ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid ◽  
Thyroid Malignancy ◽  
Review Of The Literature ◽  
Superficial Parotidectomy

Papillary thyroid carcinoma (PTC) is the most frequent thyroid malignancy. Intraparotid recurrence of PTC is, however, rare. Most parotid malignancies are either primary or metastatic from cancer outside the head and neck. We report a case of a 71-year-old man who had undergone lobectomy and completion thyroidectomy for PTC and presented to our clinic with an insidious intraparotid recurrence, for which he underwent a superficial parotidectomy and radioactive iodine therapy. We also present a review of the literature on similar cases. Intraparotid metastasis of PTC should be considered in the differential diagnosis of a parotid mass.

scholarly journals MiR-181a-5p Regulates NIS Expression in Papillary Thyroid Carcinoma

2021 ◽  
Vol 22 (11) ◽  
pp. 6067
Author(s):  
Wojciech Gierlikowski ◽  
Katarzyna Broniarek ◽  
Łukasz Cheda ◽  
Zbigniew Rogulski ◽  
Marta Kotlarek-Łysakowska
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Binding Site ◽  
Radioactive Iodine ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid ◽  
Radioiodine Treatment ◽  
Direct Binding ◽  
The Impact ◽  
First Time

NIS is a potent iodide transporter encoded by the SLC5A5 gene. Its expression is reduced in papillary thyroid carcinoma (PTC). In this study we analyzed the impact of miR-181a-5p on NIS expression in the context of PTC. We used real-time PCR to analyze the expression of SLC5A5 and miR-181a-5p in 49 PTC/normal tissue pairs. Luciferase assays and mutagenesis were performed to confirm direct binding of miR-181a-5p to the 3′UTR of SLC5A5 and identify the binding site. The impact of modulation of miR-181a-5p using appropriate plasmids on endogenous NIS and radioactive iodine accumulation was verified. We confirmed downregulation of SLC5A5 and concomitant upregulation of miR-181a-5p in PTC. Broadly used algorithms did not predict the binding site of miR-181a-5p in 3′UTR of SLC5A5, but we identified and confirmed the binding site through mutagenesis using luciferase assays. In MCF7 and HEK293-flhNIS cell lines, transfection with mir-181a-expressing plasmid decreased endogenous SLC5A5, whereas silencing of miR-181a-5p increased it. We observed similar tendencies in protein expression and radioactive iodine accumulation. This study shows for the first time that miR-181a-5p directly regulates SLC5A5 expression in the context of PTC and may decrease efficacy of radioiodine treatment. Accordingly, miR-181a-5p may serve as an emerging target to enhance the efficacy of radioactive iodine therapy.

Sign in / Sign up

Export Citation Format

Share Document